[{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Kaiser Permanente Washington Health Research","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"U.S.A","productType":"Small molecule","year":"2020","type":"Collaboration","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Amarin \/ Amarin","highestDevelopmentStatusID":"11","companyTruncated":"Amarin \/ Amarin"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"HLS Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Amarin","highestDevelopmentStatusID":"10","companyTruncated":"Amarin \/ Amarin"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Edding Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Edding Pharm","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Edding Pharm"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"MedStar Health Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Beta Oxidation","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ MedStar Health Research Institute","highestDevelopmentStatusID":"11","companyTruncated":"Amarin \/ MedStar Health Research Institute"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"DGAT","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Acyl-CoA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"Acyl-CoA","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Seqirus","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.01,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Seqirus","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Seqirus"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Edding Pharm","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Edding Pharm","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Edding Pharm"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Lotus Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Partnership","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Lotus Pharmaceutical Industries","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Lotus Pharmaceutical Industries"},{"orgOrder":0,"company":"Amarin","sponsor":"Neopharm","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"ISRAEL","productType":"Small molecule","year":"2023","type":"Agreement","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Amarin","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Amarin"},{"orgOrder":0,"company":"Amarin","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Amarin \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Not Applicable"},{"orgOrder":0,"company":"Amarin","sponsor":"Vianex S.A","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"IRELAND","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Icosapent Ethyl","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Amarin","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Amarin \/ Vianex S.A","highestDevelopmentStatusID":"12","companyTruncated":"Amarin \/ Vianex S.A"}]
Find Clinical Drug Pipeline Developments & Deals by Amarin
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
